Shin Nippon Biomedical Laboratories, Ltd. Stock Deutsche Boerse AG
Equities
YB3
JP3379950003
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.65 EUR | +1.32% | 0.00% | -27.14% |
Sales 2024 | 26.45B 169M 156M 231M | Sales 2025 * | 30.5B 194M 179M 266M | Capitalization | 55.41B 353M 326M 483M |
---|---|---|---|---|---|
Net income 2024 | 5.53B 35.27M 32.55M 48.22M | Net income 2025 * | 4.3B 27.42M 25.31M 37.49M | EV / Sales 2024 | 2.39 x |
Net Debt 2024 * | 19.51B 124M 115M 170M | Net Debt 2025 * | 22.77B 145M 134M 199M | EV / Sales 2025 * | 2.56 x |
P/E ratio 2024 |
11.4
x | P/E ratio 2025 * |
12.9
x | Employees | 1,341 |
Yield 2024 |
3.29% | Yield 2025 * |
3.76% | Free-Float | 48.8% |
1 day | +1.32% | ||
Current month | -14.53% | ||
1 month | -14.53% | ||
3 months | -20.73% | ||
6 months | -23.12% | ||
Current year | -27.14% |
Managers | Title | Age | Since |
---|---|---|---|
Ryoichi Nagata
CEO | Chief Executive Officer | 65 | 81-08-31 |
Shinji Nitanda
DFI | Director of Finance/CFO | 55 | 02-04-30 |
Terumasa Hirai
CMP | Compliance Officer | - | 84-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Ryoichi Nagata
CEO | Chief Executive Officer | 65 | 81-08-31 |
Ichiro Nagata
BRD | Director/Board Member | 38 | 17-03-31 |
Sales & Marketing | 64 | 02-10-31 |
Date | Price | Change |
---|---|---|
24-05-29 | 7.55 | -5.63% |
24-05-28 | 8 | +3.23% |
24-05-27 | 7.75 | +4.03% |
24-05-24 | 7.45 | -2.61% |
24-05-23 | 7.65 | +2.00% |
Delayed Quote Deutsche Boerse AG, May 30, 2024 at 02:02 am
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+52.36% | 56.69B | |
-3.86% | 41B | |
+38.14% | 38.11B | |
-12.01% | 26.89B | |
+14.13% | 25.59B | |
-21.62% | 18.59B | |
+0.21% | 12.39B | |
+25.96% | 11.99B | |
+23.02% | 11.88B |
- Stock Market
- Equities
- 2395 Stock
- YB3 Stock